AnaptysBio - Overview
About
Overview
Strategy
Senior Leadership
Board of Directors
Scientific Advisory Board
Contact
Science
Immune Cell Modulation
Listen to Short Takes on Deep Science
Anaptys Publications and Relevant Literature
Pipeline
Overview
Rosnilimab
ANB033
ANB101
Partnerships
Investors / News
Overview
News
Presentations & Events
Governance
Stock Information
Analyst Coverage
SEC Filings
Investor FAQs
Contact
Careers
Overview
See Where We Work
Total Rewards Program Highlights
Get to Know Our Team
Join Team Anaptys!
Contact
Toggle
Overview
Rosnilimab
Overview
Rheumatoid Arthritis
ANB033
Overview
Celiac Disease
ANB101
Partnerships
Pipeline
Development Stage and Anticipated Milestones
Therapeutic
Indication
Antibody
Program
IND Enabling
Phase 1
Phase 2
Phase 3
Rosnilimab
(Pathogenic T cell depleter)
ANB033
(CD122 antagonist)
Celiac Disease
Rheumatoid Arthritis
P1b to initiate
in 2026
Inflammatory Disease
Late-breaking data
presented at ACR 2025
Update in H1 2026
on P3 advancement
Immune Cell Modulators
P1 in healthy
volunteers ongoing
ANB101
(BDCA2 modulator)
Inflammatory Disease